Blaustein Robert 4
4 · Edgewise Therapeutics, Inc. · Filed Jan 23, 2025
Insider Transaction Report
Form 4
Blaustein Robert
Chief Development Officer
Transactions
- Award
Stock Options (Right to buy)
2025-01-21+160,000→ 160,000 totalExercise: $27.39Exp: 2035-01-21→ Common Stock (160,000 underlying) - Award
Restricted Stock Units
2025-01-21+30,000→ 30,000 totalExercise: $0.00Exp: 2035-01-21→ Common Stock (30,000 underlying)
Footnotes (2)
- [F1]Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on January 21, 2026.
- [F2]1/4th of the shares subject to the option become vested and exercisable on January 21, 2026 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.